Ascletis Begins U.S. Phase 1 Study of ASC36
Hong Kong, September 8, 2026 Ascletis Pharma Inc. has announced the initiation of a U.S. Phase 1 clinical trial...
Ascletis Pharma
Advertisement
Ascletis Joins Hong Kong Stock Connect Programs
Hong Kong, September 7, 2026 Ascletis Pharma Inc. has announced that its ordinary shares have been included as eligible...
Ascletis Starts Phase III Trial of Oral GLP-1 Drug
Hong Kong, China, August 30, 2026 Ascletis Pharma Inc. announced that the first participant has been dosed in its...
Ascletis Begins U.S. Phase I Trials of Monthly Obesity Drugs
Hong Kong, China, August 10, 2026 Ascletis Pharma Inc. has announced the initiation of two Phase I clinical studies...
AusperBio Doses First Patient for AHB-171 HBV Clinical Study
San Francisco, August 3, 2026 AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. announced the initiation of patient dosing...
Advertisements
Ascletis Launches Global Phase III Trial of Oral GLP-1 ASC30
Hong Kong – August 3, 2026 Ascletis Pharma Inc. has initiated a global Phase III clinical development program for...
Ascletis Reports ASC37 Shows Superior Weight Loss in Obesity Study
Hong Kong, July 27, 2026 Ascletis Pharma Inc. announced that its investigational ASC37, a next-generation GLP-1R/GIPR/GCGR triple peptide agonist,...
Ribo Unveils Positive Phase 2a Data for Vortosiran in CAD
SHANGHAI, China and MÖLNDAL, Sweden, July 22, 2026 Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals...
Ascletis Reports Superior ASC36_35 Weight Loss Data at EASD 2026
HONG KONG, July 23, 2026 Ascletis Pharma Inc. has announced that new preclinical data for its investigational obesity therapy...
InnoCare Doses First Patient in ICP-B208 ADC Clinical Trial
BEIJING, China, July 6, 2026 InnoCare Pharma has announced a significant milestone in its oncology pipeline with the first...
Advertisement
